Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 7;20(1):481.
doi: 10.1186/s13063-019-3563-5.

Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Jing Gan  1   2   3   4 , Yansheng Wu  1   2   3   4 , Xuezhong Gong  5 , Yiyi Ma  6 , Shengqiang Yu  7 , Jiandong Gao  8   9   10   11
Affiliations

Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Jing Gan et al. Trials. .

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disease progression. Hence, identification of alternative treatments for patients is important. The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. Because a considerable proportion of ADPKD patients presenting with chronic kidney disease (CKD) stages III-IV are diagnosed with the spleen, kidney deficiency, and blood stasis syndrome according to the diagnostic criteria of traditional Chinese medicine (TCM), we hypothesize that YNF may be a complementary drug for ADPKD patients with the corresponding syndrome. Therefore, we have designed a strict clinical trial to evaluate the safety and efficacy of YNF for ADPKD patients with CKD stages III-IV exhibiting the TCM syndrome of spleen, kidney deficiency, and blood stasis.

Methods/design: This is a multi-center prospective double-blind randomized controlled trial. The total target sample size is planned to be 72 participants, with a balanced treatment allocation (1:1). The experimental intervention will be YNF plus conventional therapy and the control intervention will be a placebo plus conventional therapy for 24 weeks. An additional 24 weeks of follow-up will be conducted after treatment completion. The primary outcome will be the estimated glomerular filtration rate (eGFR). Changes in total kidney volume (TKV), serum creatinine (Scr), blood urea nitrogen (BUN), TCM symptoms, and pain will be the secondary outcomes. Adverse events (AEs) will be monitored throughout the trial.

Discussion: This study will be the first placebo-controlled randomized controlled trial to assess whether YNF plus conventional therapy has a beneficial effect on eGFR, TKV, Scr, and BUN, and whether it can alleviate TCM clinical symptoms, reduce ADPKD-related pain, and reduce the frequency of AEs for ADPKD patients with CKD stages III-IV with the spleen, kidney deficiency, and blood stasis syndrome. The results of this trial may provide an evidence-based recommendation for clinicians.

Trial registration: Chinese Clinical Trials Register, ChiCTR-INR-16009914 . Registered on 18 November 2016.

Keywords: Autosomal dominant polycystic kidney disease; Efficacy; Randomized controlled trial; Safety; Stages III–IV chronic kidney disease; Yinang formulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient flow in the YNF study for the intention-to-treat analysis. ADPKD autosomal dominant polycystic kidney disease, BID twice daily, TCM traditional Chinese medicine, TKV total kidney volume, YNF yinang formulation
See this image and copyright information in PMC

References

    1. Meijer E, Jong PE, Peters DJ, Gansevoort RT. Better understanding of ADPKD results in potential new treatment options:ready for the cure. J Nephrol. 2008;21(2):133–138. - PubMed
    1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–1301. doi: 10.1016/S0140-6736(07)60601-1. - DOI - PubMed
    1. Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens. 2012;21(2):189–194. doi: 10.1097/MNH.0b013e32835011a7. - DOI - PubMed
    1. Dai B, Mei CL. Research on autosomal dominant polycystic kidney disease in China. Chin Med J (Engl) 2006;119:1915–1924. doi: 10.1097/00029330-200611020-00012. - DOI - PubMed
    1. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney Disease: improving global outcomes (KDIGO) controversies conference. Kid Int. 2015;88(1):17–27. doi: 10.1038/ki.2015.59. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances